Navigation Links
NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Date:5/27/2010

ed into the human body. The response is strong enough to destroy transplanted cells and tissues within hours. NewLink's HyperAcute immunotherapy exploits this hyperacute antigen-antibody response to educate a patient's immune system to attack and destroy the patient's own unmodified cancer cells.

The company's HyperAcute products are composed of irradiated, allogeneic (off the shelf), whole cancer cells that have been genetically modified to add alpha-Gal residues to cell-surface lipids and proteins. The alpha-Gal epitopes function as a molecular adjuvant, effectively harnessing the xenotransplant rejection mechanism.

About HyperAcute-Pancreas Immunotherapy

HyperAcute-Pancreas immunotherapy consists of two equal cell doses of allogeneic pancreatic cancer cell lines engineered to express the murine alpha-Gal gene. Although cells making up naturally occurring pancreatic tumors in patients do not express alpha-Gal, they share other molecules including new tumor-specific and tumor -associated antigens, with the genetically altered pancreatic cancer cells introduced by the immunotherapy. Those similarities are believed to allow the antibodies and immune cells targeting alpha-Gal to redirect their attack and destroy patient's own tumor cells.

About Pancreatic Cancer

Cancer of the pancreas is the fourth leading cause of cancer death in the United States, killing more than 35,000 Americans in 2009. The disease is divided into two broad subtypes based on histological classification: pancreatic endocrine tumors are diagnosed in 5 percent of cases, and pancreatic adenocarcinoma accounts for the remaining 95 percent. Incidence and age-adjusted mortality rates of pancreatic adenocarcinoma are nearly equal, meaning the disease is almost universally fatal. Pancreatic cancer is
'/>"/>

SOURCE NewLink Genetics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NewLink Genetics Corporation Closes $7.5 Million Financing
2. NewLink Genetics to Present Phase 2 Data on HyperAcute(R)-Pancreas Immunotherapy at the American Society of Clinical Oncology Annual Meeting
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
5. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
6. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
9. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... SAN FRANCISCO, Calif. , Sept. 2, 2015 /PRNewswire/ ... that Bonnie H. Anderson , president and chief ... Healthcare Conference on Wednesday, September 16, 2015 at 10:30 ... . The live audio webcast and ... http://investor.veracyte.com . The webcast will be available shortly after ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... and life science research, today unveiled Genedata Screener ® version 13.0 at ... in-vitro screening brings to market a rich set of new capabilities. Screener now ...
(Date:9/1/2015)... , Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... 17 th Annual Global Investment Conference sponsored by ... 8-10, 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will provide ...
Breaking Biology Technology:Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Doyle , noting that May 24 is the one-year anniversary ... Bush's ban on federal funding for embryonic stem cell ... , ,Doyle noted that Senate Majority Leader Bill Frist ... to schedule a vote on the Stem Cell Research Enhancement ...
... its way, English will become the official language of the United ... beat them to it. , ,For the first time, World ... written and spoken English in order to be among the 44 ... game is international, its football, as its called in most of ...
... new phase. Both are headed to a jumpsuit jamboree courtesy of ... ex-heads of Enron - Ken Lay and Jeff Skilling - were ... of their fellow Houstonians. The duo will soon be sentenced before ... , , When Creative Becomes Criminal , ,It is ...
Cached Biology Technology:English as the lingua franca of a new age: Its more powerful than any law 2English as the lingua franca of a new age: Its more powerful than any law 3Are there more Enrons out there? 2Are there more Enrons out there? 3Are there more Enrons out there? 4
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... , August 10, 2015 The latest ... offers comprehensive analysis of the global border security market ... revenues of $16.4bn in 2015. Now: Border security ... an example of the business critical issue you need to ... visiongain ,s objective analysis of how this will impact ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... biological molecules involved in virtually every action of every ... a recent study from the U.S. Department of Energys ... how proteins interact with drugs and other small molecules. ... in regions of high and low protein concentration ...
... January 15, 2008 The Rwandan government, Great ... the Gishwati Forest Reserve is the future site of ... of Africas most ambitious forest restoration and ecological research ... for Rwandas first national conservation park comes less than ...
... Corporate Safe Specialists (CSS),announces an addition to its ... as National Account Manager., (Photo: http://www.newscom.com/cgi-bin/prnh/20080114/AQM106 ... Currey, Sales Manager of the Company, stated, "the ... accelerate the growth we,ve seen in,networked safe sales. ...
Cached Biology News:New Argonne study may shed light on protein-drug interactions 2New Argonne study may shed light on protein-drug interactions 3Rwanda's Gishwati Forest selected as site for historic conservation project 2Rwanda's Gishwati Forest selected as site for historic conservation project 3Corporate Safe Specialists Announces Addition to Sales Team 2
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
... Cary 50 Microplate Reader accessory ... per analysis by extending the ... award-winning Cary 50 instruments. Use ... 384 samples in microlitre volumes, ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
Biology Products: